Eaton to showcase comprehensive commercial vehicle clutch portfolio at Automechanika Frankfurt
5.9.2024 12:30:00 CEST | Business Wire | Press release
Intelligent power management company Eaton today announced it is showcasing an array of aftermarket clutch solutions for the Europe, Middle East and Africa (EMEA) markets at Automechanika Frankfurt in Hall 3, booth D11. Eaton is displaying its complete line of angle spring clutches, diaphragm spring clutches, concentric pneumatic clutch actuators and ServiceRanger diagnostic solutions for commercial vehicles.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240905507731/en/
Eaton’s Advantage series automated diaphragm spring clutches are designed for all makes and models of automated manual transmissions (AMT) in the EMEA market. (Photo: Business Wire)
“We are dedicated to expanding our product portfolio to meet the changing needs of the global market and increasing customer relationships in all market channels,” said Tim Bauer, vice president, Aftermarket, Eaton’s Mobility Group.
The angle spring clutches are used for manual transmissions and are offered in two series. The Advantage series features strap drive technology that improves intermediate plate connection for more reliable performance while eliminating lug rattle and fatigue. Additionally, they are designed with a dual-seal release bearing, which allows for best-in-class 80,000-km lube intervals, reducing maintenance downtime. Eaton also offers the EverTough® series, which provides a more cost-effective solution for vehicles older than seven years.
Eaton also will be displaying its Advantage series automated diaphragm spring clutches for all makes and models of automated manual transmissions (AMT) in the EMEA market. These clutches are built to strict OEM quality standards and minimize idling noise while reducing severe vibrations and delivering outstanding performance and extended clutch life.
Eaton will also be showing its electronic clutch actuator that is designed for its UltraShift Plus transmission along with its concentric pneumatic clutch actuators (CPCAs) for DT12®, the Volvo I-Shift and Mack mDRIVE™ AMTs. The CPCAs help optimize vehicle performance by working with a vehicle’s AMT to continuously determine the ideal release position and clutch actuation when the transmission shifts. Many current AMT-equipped trucks are no longer under factory warranty, so fleet customers need reliable parts to complete repairs and maintenance. Replacing the CPCA during clutch service can help save repair time and cost while reducing downtime for unscheduled maintenance.
To support AMTs operating in the market Eaton offers its ServiceRanger™ 4 Pro Plus (SR4 Pro Plus) software. This diagnostic software and service tool is designed to support all Eaton AMTs, hybrid powertrain systems, Advantage Automated Series clutches and Eaton Cummins Automated Transmission Technologies. In addition, there is an “App Center” that allows users to calibrate all makes and models of diaphragm spring clutches and CPCAs that fit DT12®, Volvo® I-Shift and Mack mDRIVE™ AMTs.
“Eaton now offers a complete line of aftermarket clutch products in EMEA for all makes and models of trucks. Whether the truck is one year old or over fifteen years old, we have the clutch portfolio to provide our customers with cost effective solutions to keep their vehicle operating,” said Pawel Kepka, director, Aftermarket EMEA, Eaton’s Mobility Group.
Learn more about Eaton’s aftermarket solutions.
Eaton is an intelligent power management company dedicated to protecting the environment and improving the quality of life for people everywhere. We make products for the data center, utility, industrial, commercial, machine building, residential, aerospace, and mobility markets. We are guided by our commitment to do business right, to operate sustainably, and to help our customers manage power ─ today and well into the future. By capitalizing on the global growth trends of electrification and digitalization, we’re accelerating the planet’s transition to renewable energy sources, helping to solve the world’s most urgent power management challenges, and building a more sustainable society for people today and generations to come.
Eaton was founded in 1911 and has been listed on the New York Stock Exchange for more than a century. We reported revenues of $23.2 billion in 2023 and serve customers in more than 160 countries. For more information, visit www.eaton.com. Follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240905507731/en/
Contacts
Thomas Nellenbach
Thomas Nellenbach
(216) 333-2876 (cell)
thomasjnellenbach@eaton.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom